Immunservice

Immunservice is a clinical-stage biotechnology company based in Hamburg, Germany, focused on developing innovative cytokine-based immunotherapies. The company's lead program involves the administration of aerosolized Interleukin-2 (IL-2) via inhalation for the treatment of lung metastases, specifically in patients with renal cell carcinoma. By delivering IL-2 directly to the lungs, Immunservice aims to achieve high local concentrations of the cytokine to stimulate anti-tumor immune responses while avoiding the severe systemic side effects of intravenous IL-2. In addition to its therapeutic pipeline, the company offers specialized services in immune monitoring and the production of high-quality biological reagents.